Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Champions Oncology stock
Learn how to easily invest in Champions Oncology stock.
Champions Oncology Inc is a biotechnology business based in the US. Champions Oncology shares (CSBR) are listed on the NASDAQ and all prices are listed in US Dollars. Champions Oncology employs 194 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Champions Oncology
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CSBR – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
Champions Oncology stock price (NASDAQ: CSBR)Use our graph to track the performance of CSBR stocks over time.
Champions Oncology shares at a glance
|Latest market close||$7.91|
|52-week range||$7.75 - $14.68|
|50-day moving average||$8.61|
|200-day moving average||$9.74|
|Wall St. target price||$15.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.02|
Buy Champions Oncology shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Champions Oncology stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Champions Oncology price performance over time
|1 week (2022-01-13)||-2.35%|
|1 month (2021-12-16)||-3.30%|
|3 months (2021-10-16)||N/A|
|6 months (2021-07-20)||-19.12%|
|1 year (2021-01-20)||-29.81%|
|2 years (2020-01-17)||-5.83%|
|3 years (2019-01-18)||9.99|
|5 years (2017-01-20)||114.36%|
Is Champions Oncology stock undervalued or overvalued?
Valuing Champions Oncology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Champions Oncology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Champions Oncology's P/E ratio
Champions Oncology's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 402x. In other words, Champions Oncology shares trade at around 402x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Champions Oncology's EBITDA
Champions Oncology's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.7 million.
The EBITDA is a measure of a Champions Oncology's overall financial performance and is widely used to measure a its profitability.
Champions Oncology financials
|Revenue TTM||$44.4 million|
|Operating margin TTM||0.95%|
|Gross profit TTM||$19.6 million|
|Return on assets TTM||0.96%|
|Return on equity TTM||5.23%|
|Market capitalisation||$108.5 million|
TTM: trailing 12 months
Champions Oncology share dividends
We're not expecting Champions Oncology to pay a dividend over the next 12 months.
Have Champions Oncology's shares ever split?
Champions Oncology's shares were split on a 1:12 basis on 11 August 2015. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Champions Oncology shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Champions Oncology shares which in turn could have impacted Champions Oncology's share price.
Champions Oncology share price volatility
Over the last 12 months, Champions Oncology's shares have ranged in value from as little as $7.7501 up to $14.68. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Champions Oncology's is 0.9736. This would suggest that Champions Oncology's shares are less volatile than average (for this exchange).
Champions Oncology overview
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc.
Champions Oncology in the news
Microsoft's $68.7 billion deal for Activision once again shows big tech's dominance over legacy media
Could The Champions Oncology, Inc. (NASDAQ:CSBR) Ownership Structure Tell Us Something Useful?
Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that
Frequently asked questionsWhat percentage of Champions Oncology is owned by insiders or institutions?
Currently 29.286% of Champions Oncology shares are held by insiders and 64.971% by institutions. How many people work for Champions Oncology?
Latest data suggests 194 work at Champions Oncology. When does the fiscal year end for Champions Oncology?
Champions Oncology's fiscal year ends in April. Where is Champions Oncology based?
Champions Oncology's address is: One University Plaza, Hackensack, NJ, United States, 07601 What is Champions Oncology's ISIN number?
Champions Oncology's international securities identification number is: US15870P3073 What is Champions Oncology's CUSIP number?
Champions Oncology's Committee on Uniform Securities Identification Procedures number is: 158704304
More guides on Finder
Can Turo’s IPO do better than Uber and Airbnb?
Car-sharing service Turo has filed plans for an IPO. What you need to know.
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
How to buy VinFast stock when it goes public
Everything we know about the VinFast IPO, plus information on how to buy in.
How to buy Nexalin Technology (NXL) stock when it goes public
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
How to buy Specialty Building Products (SBP) stock when it goes public
Everything we know about the Specialty Building Products IPO, plus information on how to buy in.
Ask an Expert